Mitochondria-Targeted Antioxidant Compounds for ROS Scavenging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antioxidant therapies are not effectively targeted within cells, particularly mitochondria, leading to suboptimal treatment of conditions caused by excessive mitochondrial production of reactive oxygen species (ROS) and oxidative stress.
Innovation Solution
Development of compounds with quaternary cationic moieties chemically linked to antioxidant moieties, allowing for targeted delivery and accumulation in mitochondria to scavenge free radicals and reactive oxygen species.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antioxidant therapies are used, then antioxidant activity is provided, but the antioxidants are not effectively targeted to mitochondria where ROS is produced
Solution Approach 1:
The patent combines two functional moieties into a single hybrid molecule: a lipophilic cationic moiety (for mitochondrial targeting) and an antioxidant moiety (for ROS scavenging). This merging allows the antioxidant to be delivered specifically to mitochondria while maintaining its antioxidant activity, thereby resolving the contradiction between providing antioxidant activity and achieving mitochondrial targeting.
Solution Approach 2:
The lipophilic cationic moiety acts as an intermediary that facilitates the delivery of the antioxidant moiety to mitochondria. This intermediary component enables the antioxidant to overcome its natural inability to cross mitochondrial membranes and accumulate in the mitochondrial matrix, thus improving targeting capability without compromising antioxidant function.
2Ease of operation
If antioxidants are made lipophilic for mitochondrial membrane crossing, then cellular uptake is improved, but specificity for mitochondria is reduced
Solution Approach 1:
The patent merges a lipophilic cationic moiety with an antioxidant moiety in a defined molecular architecture. The lipophilic cationic portion enables membrane crossing and mitochondrial accumulation, while the antioxidant portion provides the therapeutic function. This specific combination ensures both cellular uptake and mitochondrial targeting specificity are achieved simultaneously.
Solution Approach 2:
The hybrid molecule exhibits local quality differentiation: the lipophilic cationic moiety is responsible for membrane interaction and mitochondrial accumulation, while the antioxidant moiety is responsible for ROS scavenging. This functional differentiation within the molecule ensures that mitochondrial targeting and antioxidant activity are performed by distinct structural elements, maintaining specificity.
3Adaptability or versatility
If antioxidants are administered systemically, then broad coverage is achieved, but mitochondrial concentration is insufficient
Solution Approach 1:
The patent merges mitochondrial targeting capability with antioxidant activity in a single molecule. When administered systemically, the lipophilic cationic moiety directs the antioxidant to mitochondria, achieving both systemic coverage and high mitochondrial concentration through the electrochemical gradient-driven accumulation of cationic compounds in mitochondria.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the pharmacodynamic and pharmacokinetic profiles of antioxidants, effectively treating conditions induced by mitochondrial ROS production, including neurodegenerative diseases and ocular disorders.
Implementation Method 1
The most effective way to deliver drugs specifically to mitochondria is by covalently linking a lipophilic cation such as an alkyltriphenylphosphonium moiety to a pharmacophore of interest
Implementation Method 2
compounds comprising one or more quaternary cationic moieties chemically linked to one or more antioxidant moieties for treating conditions involving oxidative stress
Data Source
AI summary
Disclosed herein are compounds for treating conditions related to oxidative stress/damage among other causes, with pharmaceutically accepted salts hydrate, solvate, optical isomer, or combination thereof, comprising lipophilic cation moieties linked to heterocyclics compounds of formula (I) and formula (8);wherein R1, R2, R3, R4, and R5 may be selected from the group consisting ofwherein X, Y, and Z are selected from the group consisting of —H, methyl, ethyl, propyl, butyl, substituted or unsubstituted aryl, and heteroaryls; n is an integer selected from 0-18, and E is a phosphorous or nitrogen atom.